All of the people who fall into the categories below warrant a referral to a family cancer clinic for genetic counselling and risk management advice.
The categories highlighted by ## have a high probability of being offered germline testing.
Those highlighted by # may be offered germline testing following review by a Family Cancer Clinic.
| Ovarian |
| Individual characteristics |
| Nil as predominately determined by pathology see below |
| Family history characteristics |
High grade invasive non-mucinous ovarian, fallopian or peritoneal cancer with a close relative* with:
• ovarian cancer, and/or
• breast cancer |
|
#
|
| A blood relative of a known carrier of a germline mutation in a cancer susceptibility gene |
## |
|
| Tumour characteristics |
| High grade invasive non-mucinous ovarian, fallopian or peritoneal cancer age <70 |
## |
|
| High grade invasive non-mucinous ovarian, fallopian or peritoneal cancer with personal history of breast cancer |
## |
|
| High grade invasive non-mucinous ovarian, fallopian or peritoneal cancer and Jewish ancestry |
## |
|
| Endometrial |
| Individual characteristics |
|
Endometrial cancer and:
• macrocephaly and/ or
• hamartomatous polyps
|
|
# |
| Endometrial cancer <50 |
|
# |
| Endometrial cancer with personal history of bowel cancer, other gastrointestinal cancer or transitional cell urothelial cancer |
|
# |
| A blood relative of a known carrier of a germline mutation in a cancer susceptibility gene |
## |
|
| Family history characteristics |
Invasive epithelial ovarian cancer with a close relative* with:
• endometrial cancer and/or
• colorectal cancer |
|
# |
|
Endometrial cancer and a close relative* with:
• endometrial cancer; and/or
• ovarian cancer; and/or
• colorectal cancer
• other gastrointestinal cancer or transitional cell urothelial cancer
|
|
# |
| Tumour characteristics |
| Endometrial cancer with abnormal mismatch repair protein immunohistochemistry |
|
# |
*Relative = 1st or 2nd degree
Note: There is additional information about the criteria for genetic testing of BRCA1 and BRCA2 and Lynch syndrome.